Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage

The quest for optimal integration of biomarker testing by tissue NGS in the care pathway: Analytics, availability and reporting of actionable vs non-actionable aberrations

Date

30 Mar 2023

Session

ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage

Topics

Laboratory Diagnostics;  Pathology/Molecular Biology;  Genetic and Genomic Testing

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Javier Hernandez-Losa

Authors

J. Hernandez-Losa

Author affiliations

  • Barcelona/ES

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.